Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I intravenous NMU-HbV study in healthy adult male volunteers
jRCT2011200004Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of HbV-101 in posthemorrhagic anemia (3 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and Clinically serious changes. Started Oct 2020; status: completed.
02
Drugs
HbV-101
03
Conditions
posthemorrhagic anemia
Beyond the preview
Go deeper on jRCT2011200004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200004.